On May 5, 2021, Humanigen announced that results from the lenzilumab Phase 3 study in hospitalized COVID-19 patients (referred to as ﾑLIVE-AIRﾒ) were published on medrxiv.org. The study achieved its pre-specified primary endpoint. In the mITT population, the Cox proportional hazard model estimated a 54% relative improvement in the likelihood of subjects treated with lenzilumab achieving SWOV compared to the placebo group.